|1.||Horiuchi, Masatsugu: 13 articles (10/2014 - 10/2002)|
|2.||Teramukai, Satoshi: 10 articles (10/2015 - 11/2008)|
|3.||Nishiyama, Akira: 10 articles (04/2015 - 07/2004)|
|4.||Ito, Sadayoshi: 10 articles (01/2015 - 09/2006)|
|5.||Shimada, Kazuyuki: 9 articles (10/2015 - 02/2009)|
|6.||Ogihara, Toshio: 9 articles (10/2015 - 02/2004)|
|7.||Rakugi, Hiromi: 9 articles (10/2015 - 02/2004)|
|8.||Saito, Ikuo: 8 articles (10/2015 - 02/2009)|
|9.||Derosa, Giuseppe: 8 articles (01/2014 - 01/2008)|
|10.||Kobori, Hiroyuki: 8 articles (03/2013 - 07/2004)|
|1.||Hypertension (High Blood Pressure)
01/01/2004 - "The present article reviews 3 head-to-head trials directly comparing the antihypertensive efficacy of olmesartan with that of 4 other AIIRAs, at recommended maintenance doses, already in clinical use for the treatment of hypertension. "
01/01/2004 - "These data indicate that, at the doses studied, olmesartan is more effective than other AIIRAs tested at their recommended doses, in terms of reduction of cuff or 24-hour ambulatory blood pressure, in patients with essential hypertension. "
09/01/2001 - "The authors conclude that olmesartan, at its starting dose, is more effective than the starting doses of the other ARBs tested in reducing cuff DBP in patients with essential hypertension."
01/01/2015 - "The efficacy of olmesartan was not negatively affected by age, sex, hypertension type, diabetes status or other concomitant clinical conditions, or cardiovascular risk factors. "
05/01/2012 - "In a multi-center, prospective study, we investigated the long-term efficacy of olmesartan by ABPM in 18-75 years-old Chinese patients with mild to moderate hypertension (clinic diastolic blood pressure [DBP] 90-109 mm Hg and systolic blood pressure [SBP] < 180 mmHg). "
01/01/2013 - "But improvement of glycemic control and insulin resistance was only observed in olmesartan group. "
11/01/2011 - "Olmesartan significantly reduced blood pressure and insulin resistance in hypertensive patients with SDB without changing BMI or SDB severity."
07/07/2008 - "In OLETF, but not LETO, rats, oral administration of olmesartan for 8 weeks ameliorated insulin resistance. "
11/01/2011 - "Effects of olmesartan on blood pressure and insulin resistance in hypertensive patients with sleep-disordered breathing."
04/01/2004 - "Olmesartan ameliorates insulin resistance and overproduction of TG in fructose-fed rats, and these effects appear to be independent of its hypotensive action."
05/01/2015 - "Different protective and reparative effects of olmesartan in stroke according to time of administration and withdrawal."
01/01/2015 - "The hazard ratios for stroke (fatal and non-fatal) were 1.48 (0.88-2.48; olmesartan plus CCB vs. olmesartan plus diuretic, P = 0.13) and 0.63 (0.39-1.02, P = 0.059) (interaction-P = 0.019). "
10/01/2014 - "Among patients aged at least 75 years, the incidence of stroke tended to be lower in the olmesartan plus CCB group than in the olmesartan plus diuretic group (hazard ratio 0.63, 95% CI 0.38-1.02, P = 0.059, interaction P = 0.019). "
05/01/2010 - "These findings suggest that olmesartan has beneficial effects in hypertensive patients with stroke and impaired CBF autoregulation, and might improve cerebral circulation and rehabilitative outcome."
05/01/2010 - "Sixteen hypertensive patients with a history of stroke received 10-20 mg olmesartan daily for eight weeks. "
11/01/2011 - "Forty-eight selected patients with cirrhosis were randomly divided into two groups of 24 patients each, those who received and those who did not receive olmesartan treatment for 1 year. "
12/01/2010 - "Olmesartan attenuated CTGF induction, reduced perivascular fibrosis and ameliorated cardiac dysfunction in a PO heart. "
12/01/2008 - "Histological analyses revealed that morphological abnormalities and fibrosis in the hearts of PAH mice recovered to the levels of normal pregnant wild-type mice after the administration of olmesartan. "
09/01/2008 - "Olmesartan also significantly prevented hepatic steatosis and fibrosis in diabetic mice. "
08/01/2008 - "These effects of olmesartan were mimicked by E64d and were accompanied by amelioration of cardiac fibrosis. "
01/01/2014 - "Collectively, these results suggest that the blood pressure lowering effect of olmesartan in KKAy mice is associated with an improvement in adipocyte, including suppression of adipocyte hypertrophy and inhibition of the adipose IL-6-oxidative stress axis. "
12/01/2008 - "Olmesartan treatment significantly lowered the blood pressure of PAH mice, and hypertrophy as well as increased plasma levels of cardiac injury markers were also markedly reduced. "
03/01/2014 - "Treatment with olmesartan significantly decreased systolic blood pressure and ventricular hypertrophy, attenuated fibrosis, and improved diastolic function (all P < 0.05). "
07/01/2015 - "The results indicate that (1) the protective effect of remote ischemic perconditioning is lost in vehicle-treated rats and that chronic treatment with Olmesartan restores the protective effect of remote ischemic perconditioning; (2) chronic treatment with Olmesartan down-regulates HIF-1α, miR-21 and miR-210 expression and reduces hypertrophy, thereby limiting ischemia/reperfusion injury; and (3) recovery of the protective effect of remote ischemic perconditioning is related to the up-regulation of HIF-1α, miR-21 and miR-210 expression."
11/01/2014 - "To assess the ability of olmesartan (OLM) to prevent or delay left ventricular remodeling and hypertrophy in patients with type 2 diabetes. "
|6.||olmesartan medoxomil (Votum)
|8.||Angiotensin Receptor Antagonists
|2.||Drug Therapy (Chemotherapy)
|3.||Sodium-Restricted Diet (Diet, Sodium Restricted)